Last Updated: June 24, 2026

Suppliers and packagers for OMNIPAQUE 240


✉ Email this page to a colleague

« Back to Dashboard


OMNIPAQUE 240

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Ge Healthcare OMNIPAQUE 240 iohexol SOLUTION;INJECTION, ORAL, RECTAL 018956 NDA GE Healthcare Inc. 0407-1401-52 10 BOTTLE, PLASTIC in 1 BOX (0407-1401-52) / 50 mL in 1 BOTTLE, PLASTIC 2004-05-25
Ge Healthcare OMNIPAQUE 240 iohexol SOLUTION;INJECTION, ORAL, RECTAL 018956 NDA GE Healthcare Inc. 0407-1411-10 10 VIAL, GLASS in 1 BOX (0407-1411-10) / 10 mL in 1 VIAL, GLASS 2004-07-15
Ge Healthcare OMNIPAQUE 240 iohexol SOLUTION;INJECTION, ORAL, RECTAL 018956 NDA GE Healthcare Inc. 0407-1412-10 10 VIAL, GLASS in 1 BOX (0407-1412-10) / 10 mL in 1 VIAL, GLASS 1985-12-26
Ge Healthcare OMNIPAQUE 240 iohexol SOLUTION;INJECTION, ORAL, RECTAL 018956 NDA GE Healthcare Inc. 0407-1412-20 10 VIAL, GLASS in 1 BOX (0407-1412-20) / 20 mL in 1 VIAL, GLASS 1985-12-26
Ge Healthcare OMNIPAQUE 240 iohexol SOLUTION;INJECTION, ORAL, RECTAL 018956 NDA GE Healthcare Inc. 0407-1412-30 10 BOTTLE, PLASTIC in 1 BOX (0407-1412-30) / 50 mL in 1 BOTTLE, PLASTIC 1985-12-26
Ge Healthcare OMNIPAQUE 240 iohexol SOLUTION;INJECTION, ORAL, RECTAL 018956 NDA GE Healthcare Inc. 0407-1412-33 10 BOTTLE, PLASTIC in 1 BOX (0407-1412-33) / 100 mL in 1 BOTTLE, PLASTIC 1985-12-26
Ge Healthcare OMNIPAQUE 240 iohexol SOLUTION;INJECTION, ORAL, RECTAL 018956 NDA GE Healthcare Inc. 0407-1413-10 10 VIAL, GLASS in 1 BOX (0407-1413-10) / 10 mL in 1 VIAL, GLASS 1985-12-26
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers and packagers for OMNIPAQUE 240

Last updated: April 25, 2026

Who Supplies OMNIPAQUE 240?

OMNIPAQUE 240 is a brand of iodinated contrast media (non-ionic, low-osmolar) used for X-ray imaging. Supply is defined by the drug’s marketing authorization holder (MAH), the manufacturer(s) named for OMNIPAQUE 240 in regulatory filings, and the label-specified contact and logistics network in each market.

What is OMNIPAQUE 240’s regulatory/brand supply chain structure?

OMNIPAQUE 240 is typically distributed in markets through:

  • MAH (marketing authorization holder) that controls brand release and regulatory obligations
  • Primary manufacturer(s) that produce the drug substance and/or final drug product
  • Secondary packer/distributor entities (in some markets) that manage packaging, labeling, and release

Because “suppliers” can mean different roles (MAH vs. manufacturer vs. distributor), buyers normally validate supply using:

  • the SmPC/label for the exact marketed product in the target country
  • the EU/UK product information that lists manufacturer and batch-release contacts
  • the US label (if applicable) that lists the manufacturer and responsible party

No market or jurisdiction was provided. Without a jurisdiction, listing “the” suppliers risks mixing different MAH/manufacturer combinations across countries.

Which suppliers are responsible for OMNIPAQUE 240?

Supplier mapping by role (how firms should categorize OMNIPAQUE 240 supply)

Role What it means in practice Where it appears
MAH Brand owner controlling regulatory status and commercial supply EU SmPC, UK PIL, national registration
Manufacturer (finished product) Produces and releases batch of OMNIPAQUE 240 EU SmPC “Manufacturer” section; US label if marketed
Distributor / packager Packages and ships in local market (release sometimes still by primary manufacturer) Local label, national contact pages

Non-exhaustive example set of supplier types (not a definitive list)

For OMNIPAQUE (iohexol) products, companies commonly involved in the product lifecycle across regions include the GE Healthcare / GE Healthcare HealthCare (historically) group entities and related manufacturing networks for contrast media, but exact named suppliers vary by country and formulation strength (240 mg I/mL).

Market-specific supplier identification

OMNIPAQUE 240 suppliers must be confirmed against the exact marketed product in the relevant jurisdiction because manufacturers and packers can differ by:

  • country registration
  • container type (vials/syringes) and pack size
  • whether the local site performs final labeling/packaging vs. only distribution

What should procurement teams require from “suppliers of OMNIPAQUE 240”?

For a defensible vendor list, procurement should obtain:

  • Manufacturer name as printed in the product label / SmPC
  • MAH name as printed in regulatory documentation
  • GMP release site(s) for finished product (batch release)
  • Distribution/packaging entity in-country (if applicable)
  • Confirmation the vendor supplies OMNIPAQUE 240 (iohexol 240 mg I/mL), not another strength (for example, 300 or 350) or a different iohexol brand

Key Takeaways

  • “Suppliers for OMNIPAQUE 240” depends on jurisdiction and the definition of supplier role (MAH vs finished-product manufacturer vs local distributor/packer).
  • The only procurement-grade supplier list comes from the label/SmPC for the specific OMNIPAQUE 240 product in the target country.
  • Without a target market, any single supplier list risks being inaccurate across countries.

FAQs

  1. Is OMNIPAQUE 240 supplied by the same manufacturer in all countries?
    No. Manufacturer and packer details can vary by national registration and packaging requirements.

  2. Who is the “supplier” to list for regulatory submissions: MAH or manufacturer?
    Regulatory submissions typically require the MAH for authorization status and the finished-product manufacturer(s) for GMP and batch-release traceability.

  3. Does OMNIPAQUE 240 have multiple strengths from the same supply chain?
    Yes. OMNIPAQUE includes multiple concentrations of iohexol; supplier identity can change by strength and packaging format.

  4. Can a local distributor be the supplier even if the product is manufactured elsewhere?
    Yes for logistics, but batch-release and GMP responsibility usually ties to the named manufacturer on the label/SmPC.

  5. What document best confirms the correct OMNIPAQUE 240 supplier?
    The product label and SmPC/PIL for the specific jurisdiction and presentation.

Sources
No sources were provided in the prompt, and no jurisdiction was specified; therefore, no supplier names can be cited accurately.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.